Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1200 - Adjuvant chemotherapy comprising a paclitaxel and carboplatin regimen or paclitaxel and ifosfamide regimen for uterine carcinosarcoma, a single institutional retrospective study


18 Dec 2016


Poster lunch


Yohei Ohtake


Annals of Oncology (2016) 27 (suppl_9): ix94-ix103. 10.1093/annonc/mdw585


Y. Ohtake1, T. Nishikawa1, H. Yoshida2, M. Ishikawa3, S. Ikeda3, T. Kato3, A. Shimomura1, T. Shimoi1, E. Noguchi1, K. Yonemori1, C. Shimizu1, M. Yunokawa1, K. Tamura1

Author affiliations

  • 1 Department Of Breast And Medical Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 2 Department Of Pathology And Clinical Laboratories, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 3 Department Of Gynecology, National Cancer Center Hospital, 104-0045 - Tokyo/JP


Abstract 1200


Uterine carcinosarcoma (UCS) is a rare form of cancer with poor prognosis. It is unclear whether adjuvant chemotherapy improves the prognosis in these patients. The aim of this retrospective study was to assess the efficacy of adjuvant chemotherapy after primary surgery for UCS.


Data for patients who underwent comlete surgical resection of UCS between 2002 and 2015 were retrospectively analyzed. The patients were classified into three groups: those who did not receive adjuvant chemotherapy (the surgery only group), those who received paclitaxel and carboplatin (TC; carboplatin AUC6 + paclitaxel 175mg/m2 q3w, 6 cycles; TC group), and those who received paclitaxel and ifosfamide (TI; ifosfamide 1.6g/m2 + paclitaxel 175mg/m2 q3w, 8 cycles; TI group).We compared the recurrence-free survival (RFS) and overall survival (OS) among the three groups.


A total of 41 patients were identified, with 20 patients in the surgery only group, 7 patients in the TC group, and 14 patients in the IT group. The patient and tumor characteristics in the surgery only group, TC group, and TI group were as follows, respectively: (mean age) 63.5; 56.0; 62.0, (clinical stage I/II/II/IV) 10/0/8/2; 1/1/3/2; 11/1/6/2, (homologous/heterologous with sarcoma component) 11/9; 5/2; 11/3, and (endometrioid/serous/not determined in carcinoma component:) 11/2/7; 1/4/2; 6/7/1. No significant differences in these characteristics were observed between the three groups. Moreover, TC or TI group did not demonstrate significant defferrence in RFS (P = 0.558, 0.410) and OS (P = 0.844, 0.663) compared with the surgery only group.


According to the findings of this study, adjuvant chemotherapy did not improve the RFS and OS in patients with UCS after complete surgical resection. However, the retrospective nature of the study and a small sample size warrant further studies for a definitive conclusion.

Clinical trial indentification

Legal entity responsible for the study

Yohei Ohtake


Japan Agency for MedicalResearch and Development


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings